Bausch + lomb and modulight announce fda approval of ml6710i photodynamic laser for use with bausch + lomb's visudyne® (verteporfin for injection)

Vaughan, ontario & tampere, finland--( business wire )--bausch + lomb corporation (nyse/tsx: blco) (“bausch + lomb”), a leading global eye health company dedicated to helping people see better to live better, and modulight corporation (“modulight”), a biomedical laser company, today announced that the u.s. food and drug administration (fda) has approved the ml6710i photodynamic laser for equivalent use with bausch + lomb's visudyne® (verteporfin for injection) photodynamic therapy (pdt) for the treatment of patients with predominantly classic subfoveal choroidal neovascularization, or the creation of abnormal choroidal blood vessels, due to age-related macular degeneration (amd).1 ml6710i is expected to be available for eye care professionals during the first half of 2023.
BLCO Ratings Summary
BLCO Quant Ranking